Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability
Open accessThe DOI matches its Crossref record; 188 of the 191 references it cites were found in a registry or an index.
Abstract
Status epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings. Benzodiazepines (BZDs) are the first-line treatment for SE worldwide due to their efficacy, tolerability, and rapid onset of action. Although all BZDs act as allosteric modulators at the inhibitory gamma-aminobutyric acid (GABA)A receptor, the individual agents have different efficacy profiles and pharmacokinetic and pharmacodynamic properties, some of which differ significantly. The conventional BZDs clonazepam, diazepam, lorazepam and midazolam differ mainly in their durations of action and available routes of administration. In addition to the common intravenous, intramuscular and rectal administrations that have long been established in the acute treatment of SE, other administration routes for BZDs—such as intranasal administration—have been developed in recent years, with some preparations already commercially available. Most recently, the intrapulmonary administration of BZDs via an inhaler has been investigated. This narrative review provides an overview of the current knowledge on the efficacy and tolerability of different BZDs, with a focus on different routes of administration and therapeutic specificities for different patient groups, and offers an outlook on potential future drug developments for the treatment of prolonged seizures and SE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Mean time from drug administration to cessation of status epilepticus (SE) in minutes is displayed for different delivery routes, based on literature research, as far as available (n.a. = not available). Intravenous (i.v.) administration showed the fastest onset of action with a latency of less than 3 min, followed by intranasal (i.n.) and intramuscular (i.m.) administration, as well as buccal and rectal delivery. Due to the heterogeneous patient populations and study settings, the displayed values should only serve as a basic guidance [48, 50, 51, 146, 186–190]. MDZ midazolam, LZP lorazepam, DZP diazepam, CZP clonazepam](https://figures.cochat.ai/paper-figures/7b44ab2840314fb286af9f300a0a85a9/benzodiazepines-in-the-management-of-seizures-and-status-epilepticus-a-review-of-figure-2.jpg)
![Fig. 3 Time from therapy administration to cessation of status epilepticus (SE) is displayed to help decide on the clinical use of different delivery routes for benzodiazepines in SE, based on published preparations and process times for drug administration via intravenous injection (i.v.), intramuscular injection (i.m.), rectal, intranasal (i.n.) and buccal administration [48]. For i.v. administration, it was assumed that no peripheral indwelling venous catheter had yet been established analogous to Silbergleit et al. [48]. MDZ midazolam, LZP lorazepam, DZP diazepam, CZP clonazepam](https://figures.cochat.ai/paper-figures/9a5a8394f39342a6908fa83a02f2e299/benzodiazepines-in-the-management-of-seizures-and-status-epilepticus-a-review-of-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-hospital benzodiazepine administration may be effective in controlling repetitive seizures or status epilepticus and avoid hospitalization 212,213 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [212]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Long-term BZD use may also be appropriate for medical conditions such as complex seizure disorders,42 spasticity,43,44 sleep disorders involving abnormal movements (e.g., rapid eye movement (REM) sleep behavior disorder, restless leg syndrome),45 and catatonia.46,47”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494 · cited 3×
“Typically, the start of SE treatment is based on t1, with the time limit being 5 min for generalized convulsive (tonic–clonic) SE, 10 min for complex focal SE (focal SE with impaired consciousness), and 10–15 min for absence SE [16].”
BackgroundA Comparison of Four Treatments for Generalized Convulsive Status Epilepticus
Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391202 · Cited by 1,325 · cited 1×
“[47] in 1988, which demonstrated a superior efficacy of LZP over phenobarbital (PB) and at least equal efficacy to phenytoin (PHT ± DZP) as a first-line treatment for SE.”
BackgroundGlauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., et al. (2016) · Epilepsy Currents · doi:10.5698/1535-7597-16.1.48 · Cited by 1,280 · cited 5×
“Therefore, even if widely used in Latin America and in many European countries, CZP is still not recommended by the latest European or American SE guidelines [38, 140].”
BackgroundInfluentialAlldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002141 · Cited by 888 · cited 2×
“[22] conducted a large placebo-controlled trial, showing that LZP at a dose of 2 mg led to seizure termination more frequently than placebo or DZP following i.”
BackgroundMethodIt’s time to revise the definition of status epilepticus
Lowenstein, D. H., Bleck, T., & Macdonald, R. L. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02000.x · Cited by 805 · cited 1×
“The 5-min time limit that usually marks the transition from a prolonged seizure to SE dates back to an operational definition proposed by Lowenstein in 1999, aimed at ensuring that patients receive treatment as soon as possible [17].”
BackgroundIntramuscular versus Intravenous Therapy for Prehospital Status Epilepticus
Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., & Barsan, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107494 · Cited by 744 · cited 3×
“LZP showed a similar rate of seizure cessation [52]; albeit, this particular randomized trial was underpowered and was based on a re-analysis of [48].”
BackgroundResultInfluentialClinical Pharmacokinetics of Diazepam
Mandelli, M., Tognoni, G., & Garattini, S. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803010-00005 · Cited by 496 · cited 1×
“The half-life of DZP is 24–48 h due to an extended redistribution into the muscle and fat tissue after initial adsorption [90].”
BackgroundBetjemann, J. P., & Lowenstein, D. H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00042-3 · Cited by 495
McIntyre, J., Robertson, S., Norris, E., Appleton, R., Whitehouse, W. P., Phillips, B., Martland, T., Berry, K., Collier, J., Smith, S., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66909-7 · Cited by 445 · cited 2×
“3 mg/kg) with regard to response rate (cessation of seizures) in paediatric patients in randomized, controlled trials [12, 75].”
BackgroundEFNS guideline on the management of status epilepticus in adults
Meierkord, H., Boon, P., Engelsen, B., Göcke, K., Shorvon, S., Tinuper, P., & Holtkamp, M. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02917.x · Cited by 433 · cited 1×
“Therefore, even if widely used in Latin America and in many European countries, CZP is still not recommended by the latest European or American SE guidelines [38, 140].”
Background
Research works printed but not linked: 9
- Rosenow F. Status epilepticus im Erwachsenenalter. In: Diener HC, Weimar C, editors. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag; 2012.
- Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17(2):106–10. · DOI · Paper page
- Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000;321(7253):83–6. · DOI · Paper page
- Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253–5. · DOI · Paper page
- Kutlu NO, Dogrul M, Yakinci C, Soylu H. Buccal midazolam for treatment of prolonged seizures in children. Brain Dev. 2003;25(4):275–8. · DOI
- Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797–808. · DOI · Paper page
- Bergamini L, Mutani R, Fariello R, Liboni W, Quattrocolo GL. Action du Ro 5 ⁄ 4023 dans le traitement des differentes formes d epilepsie. Paper given at the Rivotril Symposium, Marseilles, France. 1972.
- Bergamini L, Mutani R, Liboni W. Elektroenzephalographische und klinische Bewertung des neuen Benzodiazepin Ro 5 ⁄ 4023. EEG EMG. 1970;1:182–8.
- Tridon P, Weber M. Conduite du traitement des etats de mal epileptiques par le Ro. Sem Hop Paris. 1973;49:29.
Cited by
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
“Acquired structural aetiologies include:”
Diagnosis and management of status epilepticus: improving the status quo
Gettings, J. V., Chafjiri, F. M. A., Patel, A. A., Shorvon, S. D., Goodkin, H. P., & Loddenkemper, T. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00430-7 · Cited by 83
Rossetti, A. O., Claassen, J., & Gaspard, N. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07263-w · Cited by 78
Chowdhury, R., Bhuia, M. S., Hasan, M. S. A., Ansari, S. A., Ansari, I. A., Gurgel, A. P. A. D., Coutinho, H. D. M., & Islam, M. T. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105704 · Cited by 49
Established and emerging GABAA receptor pharmacotherapy for epilepsy
Richardson, R. J., Petrou, S., & Bryson, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1341472 · Cited by 48
Ferreira, M. D., Duarte, J. G., Veiga, F., Paiva‐Santos, A. C., & Pires, P. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020678 · Cited by 53
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“39–41 Long-term BZD use may also be appropriate for medical conditions such as complex seizure disorders, 42 spasticity, 43,44 sleep disorders involving abnormal movements (e.g., rapid eye movement (REM) sleep behavior disorder, restless leg syndrome), 45 and catatonia.”
Pina-Garza, J. E., Chez, M. G., Cloyd, J. C., Hirsch, L. J., Kälviäinen, R. K., Klein, P., Lagae, L. G., Sankar, R., Specchio, N., Strzelczyk, A., et al. (2024) · Epileptic Disorders · doi:10.1002/epd2.20243 · Cited by 42
“29 The earlier treatment proposed in our recommendations should be presented as an ideal scenario, with acceptance that this may not always be possible in real-world settings.”
InfluentialSelf-citationIntracellular calcium homeostasis and its dysregulation underlying epileptic seizures
Zhou, X., Chen, Z., Lin, X., Zhong, Y., Liu, Y., Wu, J., & Tao, H. (2022) · Seizure · doi:10.1016/j.seizure.2022.11.007 · Cited by 40
Willems, L. M., van der Goten, M., von Podewils, F., Knake, S., Kovac, S., Zöllner, J. P., Rosenow, F., & Strzelczyk, A. (2023) · CNS Drugs · doi:10.1007/s40263-023-01013-8 · Cited by 36
Self-citationAbsalom, N. L., Lin, S. X. N., Liao, V. W. Y., Chua, H. C., Møller, R. S., Chebib, M., & Ahring, P. K. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15932 · Cited by 36
Modern Sedation and Analgesia Strategies in Neurocritical Care
Bauerschmidt, A., Al-Bermani, T., Ali, S. S., Bass, B., Dorilio, J., Rosenberg, J. B., & Al‐Mufti, F. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01261-7 · Cited by 32
Benzodiazepines for the Treatment of Seizure Clusters
Penovich, P. E., Rao, V. R., Long, L., Carrazana, E., & Rabinowicz, A. L. (2024) · CNS Drugs · doi:10.1007/s40263-023-01060-1 · Cited by 30
“Many of these treatments were recently reviewed by Kienitz and colleagues [5].”
Background40 Hz Steady-State Response in Human Auditory Cortex Is Shaped by Gabaergic Neuronal Inhibition
Toso, A., Wermuth, A. P., Arazi, A., Braun, A., Grent-‘t-Jong, T., Uhlhaas, P. J., & Donner, T. H. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.2029-23.2024 · Cited by 37
Soliman, S. S., Mahmoud, A. M., Elghobashy, M. R., Zaazaa, H. E., & Sedik, G. A. (2023) · Talanta · doi:10.1016/j.talanta.2023.125238 · Cited by 25
Jindal, M., Neligan, A., & Rajakulendran, S. (2023) · Seizure · doi:10.1016/j.seizure.2023.07.022 · Cited by 25
Clinical characteristics and outcomes of patients with recurrent status epilepticus episodes
Bauer, K., Rosenow, F., Knake, S., Willems, L. M., Kämppi, L., & Strzelczyk, A. (2023) · Neurological Research and Practice · doi:10.1186/s42466-023-00261-9 · Cited by 18
“However, improvements in clinical care are required to improve emergency care, including available fast-acting benzodiazepines in the home setting [41].”
BackgroundSelf-citationSaddik, R., Brandán, S. A., Mortada, S., Baydere, C., Roby, O., Dege, N., Tighadouini, S., Tahiri, M., Faouzi, M. E. A., & Karrouchi, K. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135283 · Cited by 15
Liu, Y.-J., Zuo, L., Li, X., Nie, Y., Chen, C., Liu, N., Chen, M., Wu, J., & Guan, X. (2024) · Annals of Intensive Care · doi:10.1186/s13613-024-01390-3 · Cited by 17
A bibliometric analysis of the recent advances in diazepam from 2012 to 2021
Zhang, M., Kou, L., Qin, Y., Chen, J., Bai, D., Zhao, L., Lin, H., & Jiang, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1042594 · Cited by 23
“The half-life of diazepam increases after a drug overdose, with significant prolongation of the half-life of diazepam and its metabolites, and drug accumulation, leading to adverse drug reactions (Kienitz et al., 2022).”
BackgroundPurwien, L., Schubert‐Bast, S., Kieslich, M., Ronellenfitsch, M. W., Merker, M., Czabanka, M., Willems, L. M., Rosenow, F., & Strzelczyk, A. (2023) · CNS Drugs · doi:10.1007/s40263-023-01049-w · Cited by 17
Self-citationWillems, L. M., Beuchat, I., Fisch, U., Sutter, R., Kellinghaus, C., & Strzelczyk, A. (2025) · Neurological Research and Practice · doi:10.1186/s42466-025-00435-7 · Cited by 14
“Although intravenous (IV) applications are preferred, alternative routes (intramuscular, intranasal, rectal, or buccal) are available and may be more suitable for first responders or untrained caregivers [19, 35, 48, 91].”
Self-citationKhoueiry, M., & Alvarez, V. (2023) · Clinical Epileptology · doi:10.1007/s10309-023-00622-z · Cited by 21
Batista, F. L. A., de Araújo, S. M. B., de Sousa, D. B., Sobrinho, F. B. C., Silva, M. G. D. L., de Oliveira, M. R. C., da Costa, R. H. S., Rodrigues, L. B., Bezerra, F. S., de Azevedo, D. V., et al. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105796 · Cited by 18
van Amsterdam, J., & van den Brink, W. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112708 · Cited by 16
Alsabri, M., Elsayed, S. M., Rath, S., Abdul‐Hafez, H. A., Abo‐elnour, D. E., & Kuriam, E. (2025) · BMC Neurology · doi:10.1186/s12883-025-04323-0 · Cited by 15
“In situations where IV access is delayed or patients do not respond to the initial dosing, alternative routes, such as intramuscular or intranasal administration, and alternative agents like clonazepam, owing to its unique pharmacokinetic properties, can be considered [8].”
Kaye, A. D., Tassin, J. P., Upshaw, W. C., Robichaux, C., Frolov, M. V., Dupaquier, M. M., Fox, J., Sterritt, J., Mathew, J. S., Shekoohi, S., et al. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00628-3 · Cited by 11
Sun, M., Meng, F., Xu, Z.-Y.-R., & Guo, Y. C. (2025) · Acta Epileptologica · doi:10.1186/s42494-025-00202-w · Cited by 13
“Inhalable ASMs provide a novel approach for administering emergency treatment during CSs, SE, focal seizures, and acute seizure cluster, with several preparations already available commercially [75–77].”
Maltseva, M., Rosenow, F., von Podewils, F., Habermehl, L., Langenbruch, L. M., Bierhansl, L., Knake, S., Schulz, J., Gaida, B., Kämppi, L., et al. (2024) · Seizure · doi:10.1016/j.seizure.2024.04.005 · Cited by 11
Self-citationProgress in GABAA receptor agonists for insomnia disorder
Wang, W., Fu, W., Zhu, H., Ma, J., Zhang, J., & Qi, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432726 · Cited by 17
Status epilepticus in older adults: A critical review
Woodward, M. R., Armahizer, M. J., Wang, T. I., Badjatia, N., Johnson, E. L., & Gilmore, E. J. (2025) · Epilepsia · doi:10.1111/epi.18453 · Cited by 10
Dittrich, T. D., Vock, D., Fisch, U., Hert, L., Baumann, S. M., Kliem, P. S. C., Rüegg, S. J., Marsch, S. C. U., Marchis, G. M. D., & Sutter, R. (2024) · Neurocritical Care · doi:10.1007/s12028-024-01971-x · Cited by 8
“Midazolam administered intranasally may be an alternative when intravenous access is not available [4].”
BackgroundInfluentialWang, L., Guo, X., Qin, J., Jin, Z., Liu, Q., Sun, C., Sun, K., Li, L., Wei, X., & Zhang, Y. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07225-y · Cited by 8
Sayyed, M. E., & Hatem, S. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106173 · Cited by 9
Cost-of-illness review of status epilepticus in Europe
Strzelczyk, A., Brunklaus, A., Rosenow, F., Paprocka, J., Schubert‐Bast, S., & Kämppi, L. (2024) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2024.110105 · Cited by 8
Self-citationSeizure clusters: diagnostic and therapeutic advances
Zemberi, J., Gidal, B. E., & Kotloski, R. J. (2023) · Clinical Epileptology · doi:10.1007/s10309-023-00640-x · Cited by 8
Refinement of the pilocarpine-induced status epilepticus model in mice to improve mortality outcomes
Jiang, M., & Wang, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1592014 · Cited by 9
Lacombe, O., Plétan, Y., Grouin, J., Brennan, A., & Giré, O. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00627-4 · Cited by 7
Xin, Y., Chu, T., Zhou, S., & Xu, A. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110821 · Cited by 6
Short-Term Impact of Seizures and Mitigation Opportunities
Glauser, T. A., Becker, D. A., Long, L., Detyniecki, K., Penovich, P. E., Sirven, J. I., Peters, J. M., Rabinowicz, A. L., & Carrazana, E. J. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01350-1 · Cited by 6
Chahal, S., Rani, P., Singh, R., Joshi, G., Kumar, R., Kumar, P. P., Wadhwa, D., Singh, D., & Sindhu, J. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2400968 · Cited by 6
Akuter epileptischer Anfall – Handlungspläne für Laien (HEAL) und Therapeuten (HEAT)
Klotz, K. A., Bast, T., Strzelczyk, A., & Schubert‐Bast, S. (2023) · Clinical Epileptology · doi:10.1007/s10309-023-00619-8 · Cited by 6
Self-citationMoreau, M., Coo, H., Pattathil, N., Kukreti, V., Brooks, S. C., & Sehgal, A. (2024) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2024.04.021 · Cited by 5
Clonazepam Loading Dose in Status Epilepticus: Is More Always Better?
D’Anto, J., Beuchat, I., Rossetti, A. O., & Nový, J. (2023) · CNS Drugs · doi:10.1007/s40263-023-01012-9 · Cited by 5
“Clonazepam (CLZ) has also a favorable pharmacologic profile for SE treatment (intravenous administration and fast action) [7] and is used in many countries in that setting [8].”
BackgroundSelf-citationLange, S., Jeschke, S., Pauschek, J., Charisius, M., Makiello, P., Bertsche, T., Neininger, M. P., & Bertsche, A. (2023) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2023.109459 · Cited by 4
Decrease in wearable-based nocturnal sleep efficiency precedes epileptic seizures
Gagliano, L., Ding, T. Y., Toffa, D. H., Beauregard, L., Robert, M., Lesage, F., Sawan, M., Nguyen, D. K., & Assi, E. B. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1089094 · Cited by 6
Cui, F., Wulan, T., Zhang, Q., Zhang, V. W., & Jiang, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1371282 · Cited by 4
Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy
Zhao, H., Jiang, Q., Wang, Q., Wang, Z., Huang, Y., & Lei, T. (2026) · Cells · doi:10.3390/cells15050409 · Cited by 4
“…include enhancing γ -aminobutyric acid (GABA)-ergic inhibition and attenuating glutamatergic excitation: Phenobarbital (PB) [27], Clonazepam (CZP) [28], and Stiripentol (STP) [29] act positively on GABAA receptors, thereby enhancing inhibitory neurotransmission; Valproic Acid (VPA) enhances…”
Tan, Y., & Hashimoto, K. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104246 · Cited by 6
Song, M., Huang, M.-Z., Tao, W.-J., Yong, Z., & Su, R. (2025) · Scientific Reports · doi:10.1038/s41598-024-84440-x · Cited by 3
Die Anwendung der Salzburg-Kriterien in der Diagnose des non-konvulsiven Status epilepticus
Willems, L. M., Rosenow, F., & Strzelczyk, A. (2023) · Klinische Neurophysiologie · doi:10.1055/a-2151-0390 · Cited by 4
Self-citationAl-Mahmood, S., Alkufi, H. K., Rajab, N. A., & Alhammid, S. N. A. (2025) · Current Drug Therapy · doi:10.2174/0115748855376051250408071026 · Cited by 3
Solvent-induced photophysical properties and stability of clonazepam and Chlordiazepoxide
kian, R., Zakerhamidi, M. S., & Merajin, Z. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-30955-w · Cited by 3
“(13) or (14) imply that increasing the corresponding solvent parameter raises the energy of the excited state relative to the ground state, thereby stabilizing the ground state.”
Willert, A.-C., & Kowski, A. B. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1787808 · Cited by 4
Fadakar, H., Rudra, P., Adhikari, A., Perera, G. K., Sirimanne, V., Kaur, D., Wong, H., Yiu, K. Y., Schweitzer, D. R., & Akefe, I. O. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106242 · Cited by 3
Treatment of convulsive status epilepticus in Brazil: a review
Caboclo, L. O. S. F. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1801872 · Cited by 3
Ma, Y., Lu, C. X., Hastie, P., Bartmann, A. P., Laloyaux, C., & Borghs, S. (2025) · Epilepsia Open · doi:10.1002/epi4.70035 · Cited by 2
“With rectal diazepam and oral BZDs, the time to seizure termination is over 45 min and over 1 h, respectively, 24 which means these seizure-emergency medications may be suitable for treating seizure clusters but not prolonged seizures or status epilepticus.”
Huang, Y., Zhang, Y., & Liang, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1615079 · Cited by 5
Detyniecki, K., Strzelczyk, A., Roebling, R., Laloyaux, C., Chanteux, H., & Cloyd, J. C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01213-4 · Cited by 2
“3c) [23, 34, 108–113].”
InfluentialSelf-citationCarreño, M., Kim-Wisskirchen, I.-H., Ferré, M. F., Muñiz, P., & Valiante, C. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01493-0 · Cited by 2
“Removal of clothing and positioning of seizing adults for rectal administration can be difficult and delay administration [6, 8, 9].”
InfluentialPsychotropic drugs in pregnancy and lactation
Marazziti, D., Crowther, L. F., Arone, A., Russomanno, G., Gurrieri, R., Weiss, F., & Perugi, G. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2593995 · Cited by 2
“Lipophilic drugs such as BDZs concentrate in adipose tissue, so that a higher percentage of fat mass increases the concentration of BDZs, of their distribution volume and half-life [7,8].”
Mahama, C. N., Louisa, M., Octaviana, F., Suryandari, D. A., Budikayanti, A., & Wibowo, H. (2024) · Acta Medica Academica · doi:10.5644/ama2006-124.423 · Cited by 4
“Younger individuals may exhibit distinc underlying causes for SE (14, 74), or have different physiological responses to diazepam compared to older ones (75, 76).”
BackgroundFouche, P. F., Nichols, M., Abrahams, R., Maximous, K., & Bendall, J. (2024) · Emergency Medicine Australasia · doi:10.1111/1742-6723.14432 · Cited by 2
Recording of hippocampal activity on the effect of convulsant doses of caffeine
Eiró‐Quirino, L., YOSHINO, F. K., de Amorim, G. C., de Araújo, D. B., Barbosa, G. B., de Souza, L. V., dos Santos, M. F., Hamoy, M. K. O., dos Santos, R. G., Amóras, L. H. B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117148 · Cited by 2
Low-dose diazepam improves cognitive function in APP/PS1 mouse models: Involvement of AMPA receptors
Chen, J., Zhang, M., Shen, Z., Tang, M., Zeng, Y., Bai, D., Zhao, P., & Jiang, G. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149207 · Cited by 5
Histological and Immunohistochemical Evidence in Hypothermia-Related Death: An Experimental Study
Dervišević, E., Čamdžić, N., Lazović, E., Salihbegović, A., Sessa, F., Spahović, H., & D’Errico, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157578 · Cited by 3
“Similarly, benzodiazepines, which depress respiratory and circulatory functions, can increase the risk of hypoxia and hemorrhagic injury, contributing to the pronounced lung congestion observed in these groups [45,46].”
Morphine poisoning in a patient with malignant peritoneal mesothelioma: A case report
Zhao, C., Bai, J., Jia, S., Zhang, X., Geng, D., Li, D., Wang, Y., Gao, S., Zhang, F., & Liu, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11896 · Cited by 2
“Thus, these drugs generally decrease neuronal excitation and exhibit sedative‐hypnotic, anxiolytic and antiseizure (27).”
BackgroundHistory-dependent Biases in Perceptual Decisions Depend on NMDA ReceptorsPreprint
Toso, A., Arazi, A., Braun, A., Marin-Campos, R., Sterzer, P., de la Rocha, J., & Donner, T. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.699039 · Cited by 3
“Each experimental session began with the oral administration of the NMDA receptor antagonist memantine 73 , the GABA-A receptor agonist lorazepam 74 , or a mannitol-aerosil placebo at low dosage (both drugs and the placebo each on two randomly selected sessions).”
Alghadeer, S. M., Alsuwayegh, A., AlMuqati, H., Alammari, M. A., & Almohammed, O. A. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2496797 · Cited by 1
“This, in turn, is associated with complications such as respiratory distress, prolonged hospitalization, and the need for ICU admission [7–9].”
Carrick, F. R., Daniels, P., Pelletier, S. R., Prysmakova, S., Hankir, A. K., Abdulrahman, M., & Alrumaihi, N. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080385 · Cited by 3
Siegel, R. A., Rautiola, D., Cheryala, N., Georg, G. I., & Cloyd, J. C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114250 · Cited by 1
Zhuang, R., Zhang, Q., Miao, H., Xu, J., & Li, W. (2025) · Science Progress · doi:10.1177/00368504251401245 · Cited by 1
Sedation and analgesia strategies in the neuro intensive care unit
Merhavy, Z. I., Raeburn, T., Torres-Ayala, G. M., McCulloch, M. A., & Varkey, T. C. (2025) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v14.i4.111787 · Cited by 1
“Lorazepam is frequently used due to its efficacy and relatively longer duration of action when administered intravenously[44].”
Lei, X.-H., Yang, W., Luo, X., Rao, P.-G., & Guo, R. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s552047 · Cited by 2
“19 Multiple administration routes exist due to its lipophilicity, 20 including intranasal forms useful for patients with difficult venous access.”
Damien, C., Lefebvre, M., Torcida, N., Maeseneire, C. D., Legros, B., Depondt, C., & Gaspard, N. (2026) · Epilepsia · doi:10.1002/epi.70111 · Cited by 1
“19 BZDs are among the most prescribed drugs world-wide, with 1%–3% of the general population being chronic users, and among the more chronically abused.”
Vansoh, Z., Fothergill, R. T., Bell, F., Osborne, R., Rosser, A., Wilson, C., Stephen, J., & Chin, R. (2026) · Seizure · doi:10.1016/j.seizure.2026.01.013 · Cited by 1
Vigevano, F., Arzimanoglou, A. A., Auvin, S., Kaindl, A. M., Lynch, B., Mazurkiewicz‐Bełdzińska, M., Pujar, S. S., Smeyers, P., & Cross, J. H. (2026) · BMC Pediatrics · doi:10.1186/s12887-026-06520-3 · Cited by 1
Mohnkern, J. D., Khalid, A., Ibrahim, M., Dave, V., Chierighini, P. P., Riaño, A. S., Ajibade, T., & Shehan, T. S. M. (2026) · Prehospital Emergency Care · doi:10.1080/10903127.2026.2658592 · Cited by 1
Aeby, A., Ceulemans, B., Jansen, K., Jansen, A., Lagae, L., Leroy, P., Schoonjans, A. S., Verhelst, H., & Cilio, M. R. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03045-5 · Cited by 1
Bialer, M., Landmark, C. J., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., White, H. S., & Wirrell, E. C. (2026) · Epilepsia · doi:10.1002/epi.70346 · Cited by 4
Acute seizure therapies in people with epilepsy: Fact or fiction? A U.S. Perspective
Tatum, W. O., Glauser, T. A., Peters, J. M., Verma, A., Weatherspoon, S. E., Benbadis, S. R., Becker, D. A., Puri, V., Smith, M. C. F., Misra, S. N., et al. (2023) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2023.100612 · Cited by 1
“In addition, there is rapid bioavailability and shorter time to clinical efficacy [4,49].”
BackgroundInfluentialAnalysis and Evaluation of Prospects for the Development of New Drugs Derived from Benzodiazepines
Porseva, N. Y., Собин, Ф. В., Солонинина, А. В., Пулина, Н. А., Курбатов, Е. Р., & Dvorskaya, O. N. (2023) · Drug development & registration · doi:10.33380/2305-2066-2023-12-4(1)-1639 · Cited by 1
Stufenadaptierte Therapie des Status epilepticus
Willems, L. M., Rosenow, F., & Strzelczyk, A. (2024) · Intensivmedizin up2date · doi:10.1055/a-2115-0674 · Cited by 1
Self-citationLindane and Cetrimide lotion poisoning in an adult patient: A case report on an uncommon ingestion
Rai, P., Shrestha, S., Rijal, S., & Singh, R. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8864 · Cited by 1
Zhang, Q., Peng, S., Wei, Z., & Cheng, X. (2024) · Medicine · doi:10.1097/md.0000000000040333 · Cited by 2
“[7] However, despite the effectiveness of benzodiazepines as initial therapy, a significant proportion of patients may continue to experience seizures, necessitating the use of second-line treatments.”
Sheikholeslami, S., Baghaei, A., Amiri-Andebili, M., Salmannejad, F., & Ahmadian-Attari, M. M. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.03.004 · Cited by 1
Metabolic regulation of visual acuity
Emery, D., Vukmanic, E. V., Wang, Y., Eminhizer, M., Wang, F., Lu, X., Wang, W., Kini, T. A., Chen, Y., Fortuny, E. M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx2050 · Cited by 2
“…retina of RP pigs parallels its activity in the brain where it depresses background signaling to reverse seizures initiated by low GABA ( 30 ), demonstrating a potential off-label function for this Food and Drug Administration–approved drug in maintaining high-acuity daylight vision in…”
InfluentialA interação do consumo de álcool com uso de clonazepam
de Andrade, A. C. R., dos Santos, C. L., & de Vasconcelos, T. C. L. (2023) · Research Society and Development · doi:10.33448/rsd-v12i5.41691 · Cited by 1
Ictal-Related Chirp as a Biomarker for Monitoring Seizure ProgressionPreprint
Bahador, N., Skinner, F. K., Zhang, L., & Lankarany, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620811 · Cited by 1
Anticonvulsant and Anti-anxiety Effects of Royal Jelly in Adult Male Syrian Rats
Yaghooti, H., & Olapour, S. (2022) · Complementary Medicine Journal · doi:10.32598/cmja.12.3.1188.1
Cao, Y. (2023) · International Conference on Modern Medicine and Global Health (ICMMGH) · doi:10.1117/12.2692185
Qian, T., Gong, Q., Shu, Y., Shen, H., Wu, X., Wang, W., Zhang, Z., Cao, H., & Xu, X. (2024) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s441152
“It has specific effects, including anxiolytic, 23 sedative, 24 and hypnotic effects, 25 as well as amnesic, anticonvulsant, 26 and skeletal muscle relaxant effects.”
BackgroundAlmohaish, S., Peters, D. M., & Brophy, G. M. (2024) · Springer eBooks · doi:10.1007/978-981-99-8059-8_17
CDA-AMC (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.1019
Studying the Anti-Anxiety and Anti-Convulsant Impacts of Royal Jelly in Mice
Wolfensohn, S., Hawkins, P., Lilley, E. J., Anthony, D. C., Chambers, C., Lane, S., Lawton, M. P. C., Robinson, S., Voipio, H., & Woodhall, G. L. (2024) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/hmwea0f9v9
Le status epilepticus chez la personne adulte : le rôle essentiel du personnel infirmier à l’urgence
Tessier, W., Mileto, E., & Blais, S. (2024) · Soins d’urgence La revue de l’Association des infirmières et infirmiers d’urgence du Québec · doi:10.7202/1115272ar
Radkowski, P., Oniszczuk, H., Opolska, J., Pawluczuk, M., Gowkielewicz, M., & Grabarczyk, Ł. (2025) · Medical Science Monitor · doi:10.12659/msm.947071
“…of hypoxia-inducible factor-1 a expression [26]. receptors in the central nervous system, increases the likelihood of GABA-induced opening of the associated chloride channel, leading to a decrease in neuronal excitation, with clinical sedative and anti-anxiety effects and muscle relaxation [27].”
Ictal-interictal continuum following coil embolization of cerebral aneurysms
Huang, Q., Qian, K., Ma, J., Ma, M., Sun, L., Wei, X., & Wu, Y. (2025) · Seizure · doi:10.1016/j.seizure.2025.02.007
Octaviana, F., Harsono, A. R., Wiratman, W., Indrawati, L. A., & Budikayanti, A. (2025) · Epilepsy Research · doi:10.1016/j.eplepsyres.2025.107544
IMPACTO DO USO PROLONGADO DE BENZODIAZEPÍNICOS NA SAÚDE FÍSICA E MENTAL DOS PACIENTES
Brasileiro, B. H. V., de Sousa, L. V. M., & Azevedo, P. S. D. S. (2025) · Revista Contemporânea · doi:10.56083/rcv5n5-021
Metadata
- Authors
- Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., Schubert-Bast, S., Rosenow, F., Strzelczyk, A., & Willems, L. M.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Strzelczyk, Adam
- ORCID
- Venue
- CNS Drugs
- Published
- 2022-08-16
- Volume
- 36
- Issue
- 9
- Pages
- 951-975
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC9477921
- OpenAlex
- W4291824793
- Cited by
- 139
- References
- 191
- Citations by year
- 2026: 33 · 2025: 42 · 2024: 37 · 2023: 24 · 2022: 3
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by-nc)
- IRIS (submittedVersion, cc-by-nc)
- SERVAL (Université de Lausanne) (submittedVersion, cc-by-nc)
- Funders
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- benzodiazepines, status epilepticus, prolonged seizures, route of administration, intranasal administration, intrapulmonary administration, clonazepam, diazepam, lorazepam, midazolam, GABAA receptor, pharmacokinetics, pharmacodynamics, efficacy, tolerability, anticonvulsant therapy
- MeSH terms
- Anticonvulsants, Benzodiazepines, Clonazepam, Diazepam, gamma-Aminobutyric Acid, Humans, Lorazepam, Midazolam, Seizures, Status Epilepticus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.